AMPK-induced activation of Akt by AICAR is mediated by IGF-1R dependent and independent mechanisms in acute lymphoblastic leukemia

Department of Pediatric Hematology-Oncology, University of Miami Miller School of Medicine, 1601 N,W, 12th Avenue, Miami, FL 33136 USA. .
Journal of Molecular Signaling 09/2010; 5:15. DOI: 10.1186/1750-2187-5-15
Source: PubMed


Children with Acute Lymphoblastic Leukemia (ALL) diagnosed with resistant phenotypes and those who relapse have a dismal prognosis for cure. In search for novel treatment strategies, we identified the AMP activated protein kinase (AMPK) as a potential drug target based on its effects on cell growth and survival. We have shown previously that AICAR-induced AMPK activation also induced a compensatory survival mechanism via PI3K/Akt signaling.
In the present study, we further investigated the downstream signaling induced by AMPK activation in ALL cells. We found that AICAR-induced AMPK activation resulted in up-regulation of P-Akt (Ser473 and Thr308) and decrease of P-mTOR (Ser2448) expression and downstream signaling. We determined that activation of P-Akt (Thr308) was mediated by AMPK-induced IGF-1R activation via phosphorylation of the insulin receptor substrate-1 (IRS-1) at Ser794. Inhibition of IGF-1R signaling using the tyrosine kinase inhibitor HNMPA(AM)3 resulted in significant decrease in P-IRS-1 (Ser794) and P-Akt (Thr308). Co-treatment of AICAR plus HNMPA(AM)3 prevented AMPK-induced up-regulation of P-Akt (Thr308) but did not alter the activation of P-Akt (Ser473). Inhibition of AMPK using compound-C resulted in decreased P-Akt expression at both residues, suggesting a central role for AMPK in Akt activation. In addition, inhibition of IGF-1R signaling in ALL cells resulted in cell growth arrest and apoptosis. Additional Western blots revealed that P-IGF-1R (Tyr1131) and P-IRS-1 (Ser794) levels were higher in NALM6 (Bp-ALL) than CEM (T-ALL), and found differences in IGF-1R signaling within Bp-ALL cell line models NALM6, REH (TEL-AML1, [t(12;21)]), and SupB15 (BCR-ABL, [t(9;22)]). In these models, higher sensitivity to IGF-1R inhibitors correlated with increased levels of IGF-1R expression. Combined therapy simultaneously targeting IGF-1R, AMPK, Akt, and mTOR pathways resulted in synergistic growth inhibition and cell death.
Our study demonstrates that AMPK activates Akt through IGF-1R dependent and independent mechanisms. Co-targeting IGF-1R and related downstream metabolic and oncogenic signaling pathways represent a potential strategy for future translation into novel ALL therapies.

Download full-text


Available from: Gilles M Leclerc,
  • Source
    • "Treatment of cancer cells with AICAR also leads to cell cycle arrest in S-phase, and is associated with strong anti-proliferative effects. Numerous studies have demonstrated that AICAR can be utilized, as an effective compound to inhibit cancer cell growth, and have illustrated the efficacy of targeting AMPK in cancer therapy [103] [104] [105] [106] [107] [108] [109] [110]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Adenosine Monophosphate-Activated Protein Kinase or AMPK is a highly-conserved master-regulator of numerous cellular processes, including: Maintaining cellular-energy homeostasis, modulation of cytoskeletal-dynamics, directing cell growth-rates and influencing cell-death pathways. AMPK has recently emerged as a promising molecular target in cancer therapy. In fact, AMPK deficiencies have been shown to enhance cell growth and proliferation, which is consistent with enhancement of tumorigenesis by AMPK-loss. Conversely, activation of AMPK is associated with tumor growth suppression through inhibition of the Mammalian Target of Rapamycin Complex-1 (mTORC1) or the mTOR signal pathway. The scientific communities' recognition that AMPK-activating compounds possess an anti-neoplastic effect has contributed to a rush of discoveries and developments in AMPK-activating compounds, as potential anticancer-drugs. One such example is the class of compounds known as Biguanides, which include: Metformin and Phenformin. The current review will showcase natural compounds and their derivatives that activate the AMPK-complex and signaling pathway. In addition, the biology and history of AMPK-signaling and AMPK-activating compounds will be overviewed; their anticancer-roles and mechanisms-of-actions will be discussed, and potential strategies for the development of novel, selective AMPK-activators with enhanced efficacy and reduced toxicity will be proposed.
    Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents) 12/2014; 15(5). DOI:10.2174/1871520615666141216145417 · 2.47 Impact Factor
  • Source
    • "Additionally, AICAR can mimic other actions of AMP to exhibit AMPK-independent effects, such as the inhibition of the enzyme fructose-1,6-bisphosphatase,57 and the stimulation of muscle glycogen phosphorylase.58 However, AICAR may be useful in treating humans with acute lymphoblastic leukemia59,60 and cardiac ischemic injury.61,62 Interestingly, another recently described AMPK activator, compound 13, is taken up into the cells and converted to the AMP analog, compound 2, which is a much more potent and specific activator of AMPK when compared to ZMP.63 Compounds of this series are being optimized for oral bioavailability and pharmacokinetics; however, their clinical utility remains to be seen.63 "
    [Show abstract] [Hide abstract]
    ABSTRACT: Type 2 diabetes (T2D) is a metabolic disease characterized by insulin resistance, β-cell dysfunction, and elevated hepatic glucose output. Over 350 million people worldwide have T2D, and the International Diabetes Federation projects that this number will increase to nearly 600 million by 2035. There is a great need for more effective treatments for maintaining glucose homeostasis and improving insulin sensitivity. AMP-activated protein kinase (AMPK) is an evolutionarily conserved serine/threonine kinase whose activation elicits insulin-sensitizing effects, making it an ideal therapeutic target for T2D. AMPK is an energy-sensing enzyme that is activated when cellular energy levels are low, and it signals to stimulate glucose uptake in skeletal muscles, fatty acid oxidation in adipose (and other) tissues, and reduces hepatic glucose production. There is substantial evidence suggesting that AMPK is dysregulated in animals and humans with metabolic syndrome or T2D, and that AMPK activation (physiological or pharmacological) can improve insulin sensitivity and metabolic health. Numerous pharmacological agents, natural compounds, and hormones are known to activate AMPK, either directly or indirectly - some of which (for example, metformin and thiazolidinediones) are currently used to treat T2D. This paper will review the regulation of the AMPK pathway and its role in T2D, some of the known AMPK activators and their mechanisms of action, and the potential for future improvements in targeting AMPK for the treatment of T2D.
    Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 06/2014; 7:241-53. DOI:10.2147/DMSO.S43731
  • Source
    • "AMPKα2 deletion increases the expression and activity of NAD(P)H oxidase, ROS production and endothelial dysfunction, all of which play an important role in cardiovascular diseases, such as atherosclerosis and diabetes (Wang et al., 2010). AMPK activation by AICAR or metformin inhibits HSC proliferation via suppression of ROS production and subsequent inhibition of the AKT pathway (Leclerc et al., 2010). In present studies we found that the ratio of p-AMPK and total AMPK was lower in mice given CCl4; however , BBR treatment significantly increased the ratio of p-AMPK and total AMPK in protein expression, implying that the hepatoprotective effects of BBR on liver fibrosis may be due to the activation of AMPK. "
    [Show abstract] [Hide abstract]
    ABSTRACT: we investigated the protective effect of berberine (BBR) on chronic liver fibrosis in mice and the potential mechanism underlying the activation of AMP-activated protein kinase (AMPK) pathway. CCl4-induced chronic liver fibrosis model in mice was established and activated rat hepatic stellate cell was treated with BBR. Cell viability was evaluated by SRB assay and protein expressions were detected by Western blot. Our results showed that BBR ameliorated the liver fibrosis in mice with CCl4- induced liver injury and inhibited the proliferation of hepatic stellate cell in dose- and time-dependent manner. BBR decreased the enzyme release of ALT, AST, and ALP in serum, elevated SOD and reduced MDA content of liver tissue in CCl4- induced liver fibrosis model. BBR delayed the formation of regenerative nodules and reduced necrotic areas compared to CCl4 group. Moreover, BBR treatment activated AMPK, decreased the protein expression of Nox4, TGF-β1 and the phosphorylated Akt. The expression of smooth muscle actin (α-SMA), the marker of activated hepatic stellate cell, was also reduced by BBR treatment. Our studies firstly demonstrated that BBR exerted hepatoprotective effects possibly via activation of AMPK, blocking Nox4 and Akt expression. Our findings may benefit the development of new strategies in the prevention of chronic liver disease.
    Life sciences 01/2014; 98(1). DOI:10.1016/j.lfs.2013.12.211 · 2.70 Impact Factor
Show more